SCNI Insider Mark Germain Buys 120,000,000 Shares
Mark Germain significantly increases his stake in SCNI with a major share purchase.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mark Germain bought 120,000,000 shares of Scinai Immunotherapeutics Ltd. ($SCNI) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SCNI is down 17.6% after 1 week, down 26.8% after 1 month and down 78.4% to date (from the $3.47 close on Jun 16, 2026).
SCNI
Scinai Immunotherapeutics Ltd.
Key Points
- On June 16, 2026, Mark Germain purchased 120 million shares of SCNI, boosting his stake significantly.
- SCNI shares traded at $0.32, with other institutional investors adjusting their positions.
- CEO Amir Reichman also bought 400 million shares, indicating notable insider activity.
Get $SCNI trade alerts by text
We text you when insiders, Congress or big funds trade $SCNI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Scinai Immunotherapeutics Ltd. alert may contain errors. Disclosures
Mark Germain made a notable move by purchasing 120 million shares of SCNI on June 16, 2026. This acquisition reflects a significant increase in his investment in the company. The transaction was not part of a pre-arranged trading plan.
Other Institutional Activity in SCNI
While Germain was increasing his position, several institutional investors were adjusting theirs. XTX Topco Ltd reduced its holdings by 3,253 shares, ending with 24,041 shares valued at approximately $13,283. UBS Group AG also cut its stake by 829 shares, leaving it with 919 shares worth about $524. Meanwhile, Northwestern Mutual Wealth Management Co and Citadel Advisors LLC exited their positions entirely, shedding 1,000 and 34,562 shares, respectively.
Scinai Immunotherapeutics Ltd. Stock Down 79.3%
Shares of SCNI traded at around $0.32. The stock's recent trading activity shows a fluctuation in investor interest, with both insider and institutional transactions taking place.
Insider Buying and Selling at Scinai Immunotherapeutics Ltd.
In addition to Mark Germain's purchase, SCNI's Chief Executive Officer, Amir Reichman, acquired 400 million shares on the same day. This insider buying activity signals confidence in the company's prospects.
Bottom Line
Mark Germain's acquisition of 120 million SCNI shares is a significant development in the company's insider activity. It highlights a strong vote of confidence in SCNI from its insiders. Investors often watch such transactions closely as they can indicate management's view on the company's future potential.
Related Filing Alerts
Source: Mark Germain's Form 4 filing on $SCNI (Jun 16, 2026). Find the original filing: SCNI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts